905587-16-8

Basic information

• Product Name: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate
• Synonyms: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate;tert-butyl(S)-(1-(5-fluoropyridin-2-yl)ethyl)carbamate
• CAS NO: 905587-16-8
• Molecular Formula: C12H17FN2O2
• Molecular Weight: 240.2739832
• Mol File: 905587-16-8.mol

Chemical Properties

• Boiling Point: 324.8±32.0 °C(Predicted)
• Appearance: /
• Density: 1.115±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.26±0.46(Predicted)
• CAS DataBase Reference: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate(905587-16-8)
• EPA Substance Registry System: (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate(905587-16-8)

Safety Data

• Hazardous Substances Data: 905587-16-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is used as a building block for the synthesis of pharmaceutical agents due to its structural properties that can be incorporated into the development of new drugs.
Used in Drug Development for Cancer Treatment:
In the field of oncology, (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is used as a precursor in the development of new anticancer drugs, potentially targeting various types of cancer.
Used in Drug Development for Neurological Disorders:
(S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is also utilized in the research and development of pharmaceuticals aimed at treating neurological disorders, given its potential to interact with specific biological targets relevant to such conditions.
Used in Drug Development for Infectious Diseases:
Furthermore, (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is used in the creation of new drugs intended to combat infectious diseases, possibly due to its ability to interfere with microbial processes or enhance host defense mechanisms.
Used in Organic Synthesis:
Beyond its pharmaceutical applications, (S)-tert-butyl 1-(5-fluoropyridin-2-yl)ethylcarbaMate is used as an intermediate in organic synthesis, taking advantage of its reactivity and the stability conferred by the tert-butyl group.

Upstream product

• 905587-17-9 (S)-N-(1-(5-fluoropyridin-2-yl)ethyl)acetamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 327056-62-2 5-fluoropicolinonitrile 
• 905587-18-0 N-(1-(5-fluoropyridin-2-yl)vinyl)acetamide 
• 41404-58-4 2-bromo-5-fluoropyridine 

Downstream Products

• 905587-15-7 (S)-1-(5-fluoropyridin-2-yl)-ethanamine 
• 1073149-00-4 (S)-1-(5-fluoropyridin-2-yl)ethanamine hydrochloride 
• 915720-21-7 AZ23 

Relevant articles and documents

2-(IMIDAZ0LYLAMIN0)-PYRIDINE DERIVATIVES AND THEIR USE AS JAK KINASE INHIBITORS

The present inv ention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A is 5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl is optionally substituted on carbon with one or more R6

CHEMICAL COMPOUNDS 000-1

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors

The design, synthesis and biological evaluation of a series of pyrazol-3-ylamino pyrazines as potent and selective JAK2 kinase inhibitors is reported, along with the pharmacokinetic and pharmacodynamic properties of lead compounds.

PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.

5-AMINOPYRAZOL-3-YL-3H-IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.

AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases

The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4- aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of 10z (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.

CHEMICAL COMPOUNDS

This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.